Haier Biomedical's International Revenue Reaches New Heights

Haier Biomedical, based in Qingdao, China, reported a notable financial performance for 2025. The company's overseas revenue surged by 17.9% year-on-year to 840 million yuan, contributing to 36% of its total revenue, which reached 2.33 billion yuan. This growth marks a significant milestone in the company's global expansion strategy.

Despite challenges in the global trade environment, Haier Biomedical achieved double-digit revenue growth in markets across Europe, Asia-Pacific, the Americas, and Africa. The Asia-Pacific region alone saw a 26.0% growth. The company attributes its success to a new strategic blueprint focusing on market, industry, and model leaps to create an integrated life science platform.

Innovation played a crucial role, with AI-powered applications accounting for 15% of total revenue. The firm's R&D efforts saw investment grow by 50% to 320 million yuan, resulting in 1,620 new patents.